January 13, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) shares over potential securities laws violations by Anthera Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) concerning whether a series of statements by Anthera Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Hayward, CA based Anthera Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune disease. Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) reached in 2015 as high as $10.91 per share.

On November 10, 2016, Anthera Pharmaceuticals Inc announced that the CHABLIS-SC1 clinical trial with blisibimod for the treatment of systemic lupus erythematosus (SLE) failed to meet its primary endpoint based upon the SLE Responder Index-6 (SRI-6) at 52 weeks.

On December 27, 2016, Anthera Pharmaceuticals Inc announced that its SOLUTION Phase 3 Study for liprotamase also failed to meet its primary endpoint. The Company announced it would conduct a new study of liprotamase.

Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) declined to as low as $0.64 per share on December 30, 2016.

On January 13, 2017, NASDAQ:ANTH shares closed at $0.67 per share.